Abstracts tagged "Oncology and adverse events"

Abstract Number: 2140 • 2019 ACR/ARP Annual Meeting
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Linda Laaouad¹, Janet Roberts ², Daniel Ennis ³, Carrie Ye ⁴, Karam Al Jumaily ⁵, Marie Hudson ⁶, Shahin Jamal ⁷, Janet Pope ⁸, Tatiana Nevskaya ⁹, Alexandra Saltman ¹⁰, Megan Himmel ¹¹, Aurore Fifi-Mah ¹², Annaliese Tisseverasinghe ¹³, Nancy Maltez ¹⁴, Ines Colmegna ¹⁵ and Sabrina Hoa ¹⁶, ¹University of Montreal, Montreal, Canada, ²Dalhousie University, Halifax, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Alberta, Edmonton, Canada, ⁶Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Western University, London, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Calgary, Calgary, AB, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵McGill University Health Center, Montreal, QC, Canada, ¹⁶University of Montreal, Montreal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].